There is a wealth of evidence that angiotensin converting enzyme (ACE) inhibitors improve symptoms, morbidity and mortality in patients with heart failure. In this context the use of ACE inhibitors could be considered a tool with which to assess the effect of trial design and methodology on the ability to detect improvement in symptoms and exercise performance.
Introduction
It is generally agreed that angiotensin converting enzyme (ACE) inhibitors improve symptoms, morbidity and prognosis in patients with heart failure due to impaired left ventricular systolic dysfunction. Recent studies have tended to concentrate on the prognostic benefits of ACE inhibitors but many clinicians still believe that the primary aim of treatment in patients with more severe heart failure is to relieve symptoms. This should be reflected by an increased ability of the patient to perform tasks such as walking and climbing stairs, that is, an improvement in functional capacity and exercise performance.
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Two recent reports have highlighted the possibility that earlier studies may have over-estimated the benefits of ACE inhibition in respect to exercise performance. The V-HeFT-II study (Vasodilator-Heart Failure Trial II) showed that the combination of nitrates and hydralazine improved exercise performance to a greater extent than ACE inhibitors, while one of the largest placebo-controlled studies on the effects of an ACE inhibitor on exercise capacity conducted to date failed to show a difference in exercise duration, though symptoms did improve 11 ' 21 . Therefore, a review of studies comparing placebo and ACE inhibitors on exercise seems timely.
Exercise testing has been adopted as a more objective measure of improvement than symptoms in patients with chronic heart failure. However, it is now clear that there is also a large subjective component to exertional capacity. Although repeat testing can reduce the variability in exercise performance, a placebo Evaluation of heart failure treatment 121 response still occurs' 31 . Most studies do indicate that ACE inhibitors improve symptoms and this should presumably not be subject to technical problems even though the methods of collecting the information may be flawed.
We took the view that the evidence that ACE inhibitors improve symptoms in patients with heart failure is incontrovertible, and therefore, the inability of exercise testing or symptom scoring to show a benefit in any particular study was due to a defect in study methodology or patient entry criteria or occurred by chance. In this context the use of ACE inhibitors could be considered a tool with which to assess the effect of trial design and methodology on the ability to detect improvement in symptoms and exercise performance.
This overview is not a statistical meta-analyses of the studies concerned, but an overview to compare and contrast their methodology and its effect on outcome. The main objective is to determine whether exercise testing is a reliable method to evaluate the clinical efficacy of treatment for patients with symptomatic heart failure and to determine which study designs, patient entry criteria and/or exercise testing methods are most successful in detecting differences between placebo and an active agent. A further objective was to address the concordance or otherwise between symptomatic improvement and increase in exercise duration.
Methods

Selection of trials
Published trials evaluating the effect of ACE inhibitors on exercise capacity in patients with symptomatic chronic heart failure were identified using Medline and Current Contents databases, and by review of relevant reference lists. Only studies which compared the effects of an ACE inhibitor with placebo in a double-blind, randomized manner were selected. Studies evaluating asymptomatic patients with left ventricular dysfunction were not included. Most studies included patients with heart failure due to different aetiologies. Keren et al. [4] exclusively included patients with dilated cardiomyopathy, while Dickstein et al.
[S] studied only postinfarction patients with heart failure. Studies of less than 24 h duration were excluded.
Analysis of studies
The outcome of studies regarding the effect of ACE inhibitors on exercise capacity and symptoms was noted and whether these outcomes were consistent with each other. Studies were examined to determine whether the following factors might influence the likelihood of a positive outcome: use of a cross-over or parallel group study design; study size; use of treadmill versus bicycle exercise test; year of publication; severity of heart failure; duration of treatment; differences between ACE inhibitors.
The percentage change in exercise duration from baseline in different studies was noted and compared in the active and the placebo groups. Percentage changes, as opposed to absolute values, were used to try to produce an approximate comparison between studies using different exercise protocols. Data have been presented as mean ± 1 SD unless indicated otherwise.
Results
Thirty-five double-blind trials were identified where the effects on exercise performance of an ACE inhibitor were compared to a placebo in patients with symptomatic heart failure ( Tables 1-8) . Taking all studies together 3411 patients with symptomatic chronic heart failure were involved.
Effect on exercise capacity and symptoms
Thirty-three trials documented patient symptoms, and in 25 (76%) there were statistically significant improvements. Of the thirty-five trials reviewed, 23 (66%) documented a statistically significant improvement in exercise duration and/or workload. Twelve studies failed to find a significant difference in exercise capacity between the active and placebo groups.
Mean improvement in exercise duration in terms of percent change from baseline was 19% for the active group (adjusted for number of patients in each study; range 3 to 89%; data from 27 studies). The mean change for the placebo group was 7% (range -2 to 79%; 25 studies). When only studies with size of more than 50 patients were considered, the mean improvement in the active group in nine such studies was 19% (range 4 to 29%) compared to 5% (range -2 to 10%) in the placebo group.
Concordance between exercise capacity and symptoms
In 27 of the 33 trials (i.e. 82%), there was concordance between the effect on symptoms and that on exercise capacity. Twenty-one showed improvement in both, while six could find neither exercise capacity nor symptoms to be favourably affected. There were six trials where there was a discrepancy between the effect on exercise capacity and symptoms. Four studies found improved symptoms only and two improved exercise capacity only. Taken together, studies which found symptom improvement following ACE inhibitor therapy also found exercise duration to be better in the active group than in the placebo group (34 ±24% vs 12 ±12%; f=0002; 15 studies; Fig. 1 
3%
A = active group; P = placebo group; NA = data not available. *discrepancy between effect on exercise capacity and symptoms. in exercise duration (placebo and active groups: 20 ±31% and 10 ± 4%, respectively; P=ns; six studies).
Study design Cross-over design studies
Five (83%) of the six cross-over studies showed an improvement in either symptoms or exercise capacity compared to placebo. Three (50%) studies showed an improvement in exercise capacity. Two of the six crossover trials showed an improvement in both exercise performance and symptoms on ACE inhibitor therapy, while two showed a significant improvement in symptoms only and one in exercise capacity only. One crossover study that showed neither an improvement in symptoms or exercise performance used a corridor walk test, was conducted in elderly patients and treatment was only for 3 weeks.
Parallel design studies
Twenty-two (76%) of the 29 parallel design studies demonstrated either a significant improvement in symptoms or exercise capacity. Twenty (69%) of the 29 studies demonstrated a significant improvement in exercise performance. Two studies showed a significant improvement in symptoms but not exercise capacity. Five studies failed to show an improvement by either outcome. In two small studies, details of symptomatic assessment were not available and exercise capacity did not increase significantly.
Effect of study size
Study size in different trials varied from 12 to 443 patients (median 36). Although in the overall group only 23 of the 35 trials showed a positive effect on exercise capacity, of the 15 studies with size more than 50 patients, 13 demonstrated an improvement in exercise capacity. Symptomatic improvement also occurred in 13 of these 15 studies. There were 12 trials with a study size of more than 100, and all but one of these showed improvement in exercise capacity.
Small studies also produced discrepant results more frequently, in terms of the effects on exercise capacity and symptoms. Four of the six trials with discrepant results had study size less than 50.
Use of treadmill vs bicycle
Eighteen trials used a treadmill, 12 used a bicycle and three used both methods for measuring exercise capacity. Data were separately available for treadmill and bicycle ergometry testing in the three trials using both methods. Hence, data from 21 treadmill and 15 bicycle studies were analysed.
Sixteen of the 21 (76%) treadmill studies were positive while five showed no difference from placebo. On the other hand, only eight of the 15 bicycle studies (53%) were positive while seven could not show improved exercise capacity. When trials with study size more than 50 were considered, all the nine treadmill trials were positive while only five of the eight bicycle ergometry trials showed a positive response.
Furthermore, examining the studies with discrepant results, it was noted that four studies had found symptomatic improvement but not an improvement in exercise capacity. Three of these four studies used bicycle ergometry one of which was the only study with more than 100 patients not to show improved exercise capacity with an ACE inhibitor.
There were three studies which had used both treadmill and bicycle ergometry for exercise testing. One of these studies found an improvement in exercise capacity in patients tested by treadmill, but not in those treated by bicycle ergometry 161 . In no case was the reverse found.
Corridor walk test failed, overall, to show a difference between active and placebo in the three studies where they were used' 
Peak oxygen consumption
Peak oxygen consumption was reported in the doubleblind phase of nine studies' 5 ' 7 " 14 '; it did not increase significantly in five studies, none of which showed an improvement in exercise duration. Conversely, peak oxygen consumption improved in four studies, all of which also showed an improvement in exercise duration' 7 ' 8 ' 10 "'. The increase in peak oxygen consumption in the latter studies averaged 2-3 ml. kg" ' . min"'. ' .
The effect of repeated baseline tests
Duration of treatment
Duration of follow-up varied form 3 weeks to 1 year. Seven studies had a follow-up of 8 weeks or less. Two showed an improvement in both exercise capacity and symptoms, two showed an improvement in symptoms alone and one showed an improvement in exercise capacity only. Fifteen of the 21 studies with a follow-up of 12 (20 studies) or 14 weeks (one study) showed improvement in exercise capacity. Of 20 such studies where symptoms were documented, 16 showed improvement in symptoms. Four studies followed-up their patients for 6 months and all these were positive in terms of exercise capacity as well as symptoms. Three studies had a follow-up of 11-12 months and only one of these showed an improvement in exercise capacity. This study also showed an improvement in symptoms.
Year of publication
Ten (71%) of the 14 studies published during or before 1987 (the year of the CONSENSUS study publication -Cooperative North Scandinavian Enalapril Survival Study) showed improved exercise performance and 11 showed an improvement in symptoms. On the other hand, only 12 (57%) of 21 studies published after 1987 showed improved exercise capacity, and 11 of these 12 also showed an improvement in symptoms.
Drug class effect
Six of the 12 studies on enalapril, six of nine studies on captopril, three of four studies with cilazapril, two of three studies with lisinopril and each of the studies with quinapril (three studies), perindopril (one study), benazepril (one study) and fosinopril (one study) were positive for improved exercise capacity. The solitary study reported on ramipril did not find an improvement in exercise capacity though symptoms did improve. Symptomatic improvement occurred in eight of 12 studies with enalapril, six of nine studies with captopril, two of three studies with quinapril, one of three cilazapril studies, and each of the studies with lisinopril (three studies), perindopril (one study), benazepril (one study), fosinopril (one study) and ramipril (one study). Overall, the favourable effect of ACE inhibitors in patients with heart failure does not appear to be limited to any particular ACE inhibitor.
Dose of A CE inhibitor
A study using cilazapril 19 ' in doses of 0-5 mg to 2-5 mg . day"' showed no difference from placebo while a study of quinapril, comparing placebo, 5 mg, 10 mg and 20 mg b.d. showed a clear dose-response 119 '. A study of captopril given 25 mg once or twice daily in elderly patients showed no benefit compared to placebo 1 ' 4 '. Northridge's study of quinapril showed that 20 mg once daily and 10 mg b.d. were equally effective compared to placebo' 32 '. The lowest dose of ACE inhibition that appeared effective in improving symptoms and/or exercise capacity are shown in Table 10 .
Discussion
The high concordance (82%) between the ability of a study to show changes in exercise capacity and symptoms supports the view that exercise testing may be a useful, and possibly less subjective, adjunct to assess the clinical response of patients with symptomatic heart failure to therapeutic interventions. It could also be argued that there is little point in measuring the same outcome in different ways and that symptoms are the more relevant outcome to the patient and clinical practice. However, objective evaluation of exercise performance seems well advised before entering patients into a study to assess symptoms in heart failure as the test will help describe the patient population and help identify patients in whom ischaemia or arrhythmias may be contributing to symptoms and exercise intolerance. Three factors were found to be important in determining the outcome of parallel design studies. These were the study size, duration of follow-up, and method of exercise testing. There were nine trials with study size more than 50, follow-up of 3-6 months, and which tested the exercise performance by treadmill. All these eight studies were able to show improved exercise capacity as well as symptoms.
Duration of follow-up
Many trials found exercise duration to increase progressively on serial assessment, at least until 12 (Fig. 2 ). An inadequate duration of follow-up, therefore, may miss a true response to treatment. However, of the three trials that had a follow-up of greater than 11 months, the two largest were unable to show an improvement in symptoms or exercise capacity. This may indicate either that the benefits of ACE inhibitors do not persist or that long periods of follow-up may introduce confounding factors such as intercurrent illness (e.g. injury, malignancy) or variable rates in the deterioration of the underlying heart disease (e.g. myocardial infarction). Much larger studies may be required to distinguish the effect of ACE inhibitors from the background 'noise' in very long-term studies. Several studies suggest favourable long-term effects on morbidity and mortality 
Treadmill vs bicycle testing
On balance, treadmill exercise testing appeared more effective in discriminating between placebo and the active treatment. There could be several reasons for the higher sensitivity of treadmill testing as opposed to bicycle ergometry. Treadmill exercise testing provokes higher peak oxygen consumption, reflecting greater cardiopulmonary stress 139 ' 401 . Bicycle exercise testing stresses a smaller muscle bulk and this may lead to muscle fatigue and discomfort rather than cardiopulmonary efficiency limiting exercise performance. Wilson et a/.
14 ' 1 found that in patients with chronic heart failure, respiratory gas analysis during maximal bicycle exercise could not be used to measure maximal VO 2 . However, it is likely that there is great cultural variation in bicycle exercise preference and efficiency. Cowley et a/.
1421 studied different exercise protocols in patients with heart failure (two treadmill protocols, a corridor walk test and pedometer scores of customary activity). They found no correlation between different tests and concluded that 'different methods of assessing exercise capability provide different measures of patients' incapacity'. Though all the above lines of evidence are indirect and the present overview can only be considered hypothesisgenerating, it appears that treadmill may be better than bicycle ergometry in evaluating a therapeutic response in patients with heart failure.
Cross-over vs parallel design studies
The use of cross-over as opposed to a parallel study design was not found to be a major determinant of outcome. Indeed if a significant improvement in symptoms or exercise capacity is taken as a positive outcome than cross-over trials may even be more effective than parallel design studies in showing a response. There are a number of disadvantages to cross-over trials. Studies of long-duration are impractical as at least two treatment periods are employed. Analysis of cross-over trials may be confounded by order or period effects, although this was not a problem in the studies reported here. Thus an ACE inhibitor could improve clinical status which may then be maintained during the placebo period; an order effect. A washout period between treatments may be employed to try to avoid this sort of problem, but it is not clear that a washout period is needed if the study periods themselves are of sufficient duration. The natural history of chronic heart failure is that it gradually deteriorates with time so that the second treatment may tend to do less well than the first treatment, whether it is active or not; a period effect. However, a wealth of studies in heart failure suggest that patients in NYHA II-III have little change or even an improvement in exercise capacity and symptoms during treatment with placebo for up to 6 months. This suggests that cross-over trials of up to 6 months duration are working on a stable background as far as the tests employed are concerned.
One advantage of the cross-over design is that the patients serve as their own control. Because of the greater inter-individual variability, as opposed to the variation within an individual over relatively shortperiods of time, parallel design studies need to have a larger sample size to avoid baseline differences and the marked placebo response observed in some individuals. In the cross-over trial each patient is evaluated twice, effectively doubling the size of the study. A further advantage of the cross-over trial is that because it requires fewer patients it can be conducted in a limited number of centres leading to a greater uniformity in clinical practice and testing. There are advantages to a parallel design study. Firstly it is more practical for studies that require treatment periods longer than 3 months. Secondly, because it treats a larger heterogeneous group the outcome may be more widely applicable. There is no consensus on how to handle data from patients dropping out both from cross-over and parallel design studies, but effectively more data are lost from a cross-over trial design.
It would seem the cross-over trial is ideal for the initial evaluation of interventions, allowing a well defined group to be carefully studied over the short-or medium-term. This study design is optimal for intensive assessments of the effects of interventions on renal function, electrolytes and neuro-endocrine variables. The parallel design study is better placed to evaluate interventions that have shown promise in the earlier cross-over trials and is essential for the evaluation of long-term morbidity and mortality.
The effect of repeated baseline tests
Although repeated baseline exercise testing has been strongly advocated 131 this did not seem to have a major bearing on the ability of trials of ACE inhibitors to show differences from placebo. Indeed of the 12 studies that failed to show a difference in exercise performance, the three best designed, and therefore most surprisingly negative, all had one or more baseline tests . It is possible that pressure on the investigator to produce a reproducible baseline exercise test study subtly alters patient performance and could under some circumstances enhance the apparent placebo effect.
Oxygen consumption
Although measurements of physiological gas exchange help understanding of the pathophysiology of heart failure, there is no evidence from the trials of ACE inhibition that such measurements are superior in distinguishing active from placebo therapy than exercise duration alone. Indeed as a rather high proportion of studies measuring oxygen consumption failed to show a difference between ACE inhibitor and placebo it could be argued that these relatively complex and cumbersome measurements may interfere with the results of exercise testing.
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Severity of heart failure
More studies published before or during 1987 found improved exercise performance than studies published after 1987 (71% vs 57%). It is possible that the results of the CONSENSUS trial led to inclusion of patients with milder degrees of chronic heart failure in subsequent trials. Indeed the data from 21 studies where NYHA class of patients was available showed that studies conducted after 1987 included more patients with NYHA class U (69% vs 29%) than class III (29% vs 60%) or class IV (0-6% vs 11%) ( Table 9) .
Dose
The studies reported here suggest that a wide range of doses of ACE inhibitors can improve symptoms and/or exercise performance in heart failure. Of the four studies that compared dosing regimes, only one suggested that higher or more frequent doses were more effective. Currently, the NETWORK, ATLAS (Assessment of Treatment with Lisonopril and Survival) and ACHIEVE (Accupril Congestive Heart Failure Investigation and Economic Variable Evaluation) studies are comparing the effects of a range of doses of ACE inhibitors on morbidity and mortality in heart failure and should provide robust information on the relationship between dose and the relief of symptoms' 451 . To summarize, the present overview confirms that ACE inhibitors do improve exercise capacity as well as symptoms of patients with chronic heart failure. In the overall analysis, changes in exercise capacity are consistent with changes in symptoms. Study size, duration of follow-up and method of exercise testing appear to be three factors affecting the outcome of the studies. Clearly greater efforts are required to define the power of the study prior to initiation of the investigation. Treadmill testing appears to be more sensitive than bicycle ergometry in detecting a therapeutic response. As exercise testing is increasingly used in routine evaluation of patients with chronic heart failure and their response to therapy, there is a need for more research into exercise protocols for this purpose.
